Details of the Drug

General Information of Drug (ID: DMU62I8)

Drug Name

CX2009

Indication

Disease Entry	ICD 11	Status	REF
Neoplasm	2A00-2F9Z	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Probody drug conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Activated leukocyte cell adhesionmolecule (ALCAM)	TT2AFT6	CD166_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04596150) Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of CytomX Therapeutics.